We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others... Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Show more
DALLAS, July 02, 2024 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX), (βBlackboxβ or the βCompanyβ), a financial technology and social media hybrid platform offering real-time...
DALLAS, May 16, 2024 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX), (βBlackboxβ or the βCompanyβ), a financial technology and social media hybrid platform offering real-time proprietary...
DALLAS, April 02, 2024 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX), (βBlackboxβ or the βCompanyβ), a financial technology and social media hybrid platform offering real-time...
DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX), (βBlackboxβ or the βCompanyβ), a financial technology and social media hybrid platform offering real-time...
DALLAS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Blackboxstocks Inc. (NASDAQ: BLBX) (βBlackboxβ or the βCompanyβ), a financial technology and social media hybrid platform offering real-time proprietary...
-Blackbox Stockholders to retain 26.7% of the combined companyβs 12,000,000 common shares post-merger plus receive a Contingent Value Right (βCVRβ) for current Blackbox fintech operations...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.78 | -12.4600638978 | 6.26 | 6.3399 | 5.4005 | 29868 | 5.8360154 | CS |
4 | -0.76 | -12.1794871795 | 6.24 | 7.247 | 5.4005 | 27488 | 6.44973236 | CS |
12 | -11.45 | -67.6314235086 | 16.93 | 16.93 | 5.4005 | 30989 | 8.72747859 | CS |
26 | -4.45 | -44.8136958711 | 9.93 | 17.49 | 5.4005 | 29565 | 10.66751266 | CS |
52 | -10.52 | -65.75 | 16 | 17.49 | 3.8 | 96873 | 10.59421549 | CS |
156 | -147.72 | -96.4229765013 | 153.2 | 180.8 | 3.8 | 1080996 | 47.59500472 | CS |
260 | -39.92 | -87.9295154185 | 45.4 | 348 | 3.8 | 1566346 | 97.07769313 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions